Comparing adrenal venous sampling outcomes in primary aldosteronism with concurrent versus discontinued use of mineralocorticoid receptor antagonist: a randomized-controlled trial

Comparing adrenal venous sampling outcomes in primary aldosteronism with concurrent versus discontinued use of mineralocorticoid receptor antagonist: a randomized-controlled trial.

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

TCTR

Registry ID

TCTR20230908002

Enrollment

Registered

2023-09-08

Start date

2023-08-16

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with a confirmed diagnosis of PA according to the criteria of the Endocrine Society Clinical Practice guideline 2016. Continue MRA, discontinue MRA, Primary aldosteronism, lateralization index, contralateral suppression index

Interventions

If previously receiving MRA (in this study, spironolactone) continue taking spironolactone, if previously receiving other antihypertensive drugs the patient will be switched to spironolactone and afte

Active Comparator Drug,Active Comparator Drug

Continue MRA,Discontinue MRA

Eligibility

Sex/Gender

All

Age

20 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Patients with a confirmed diagnosis of PA according to the criteria of the Endocrine Society Clinical Practice guideline 2016 2. Be ready and have indications for doing AVS 3. AVS results with a selectivity index confirm that the catheter is in the adrenal vein and AVS results confirm that it is in unilateral form. 4. 20-70 years old

Exclusion criteria

Exclusion criteria: 1. Patients who do not consent to AVS 2. Patients who can skip unilateral adrenalectomy without AVS 2.1 Patients < 35 years old with unilateral adenoma on CT or MRI with obvious PA characteristics (PAC > 30 ng/dL and spontaneously low potassium). 2.2 Patients suspected of adrenal cancer (adrenocortical carcinoma) 3. Patients diagnosed with familial hyperaldosteronism type I and III.

Design outcomes

Primary

Measure	Time frame
Lateralization index 4-8 month after intervention serum aldosterone/cortisol of dominant side, non dominant side ,Contralateral suppression index 4-8 months serum aldosterone/cortisol of non dominant side, IVC	—

Secondary

Measure	Time frame
clinical and biochemical outcome after unilateral adrenalectomy 3 months, 6 months blood pressure, antihypertensive drug, potassium, PAC, DRC	—

Countries

Thailand

Contacts

Public ContactSittikul Thipbumrung

Chiang Mai University

sittikul_2@hotmail.com0897326494

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026